Hussman Strategic Advisors, Inc. Editas Medicine, Inc. Transaction History

Hussman Strategic Advisors, Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 08, 2023	BUY	$8.32 - $13.21 $171,392 - $272,126	20,600 Added 198.08%	31,000 $274,000
Q4 2021 Jan 31, 2022	SELL	$26.55 - $40.57 $217,710 - $332,674	-8,200 Reduced 44.09%	10,400 $276,000
Q3 2021 Nov 01, 2021	SELL	$39.27 - $72.94 $486,948 - $904,456	-12,400 Reduced 40.0%	18,600 $764,000
Q2 2021 Aug 03, 2021	BUY	$31.29 - $56.64 $519,414 - $940,224	16,600 Added 115.28%	31,000 $1.76 Million
Q1 2021 May 03, 2021	SELL	$39.71 - $90.58 $649,258 - $1.48 Million	-16,350 Reduced 53.17%	14,400 $605,000
Q4 2020 Feb 01, 2021	SELL	$27.07 - $84.35 $1.24 Million - $3.86 Million	-45,750 Reduced 59.8%	30,750 $2.16 Million
Q3 2020 Nov 02, 2020	SELL	$28.06 - $37.16 $715,530 - $947,579	-25,500 Reduced 25.0%	76,500 $2.15 Million
Q2 2020 Jul 31, 2020	SELL	$18.5 - $34.34 $9,250 - $17,170	-500 Reduced 0.49%	102,000 $3.02 Million
Q1 2020 May 01, 2020	BUY	$14.88 - $32.78 $535,680 - $1.18 Million	36,000 Added 54.14%	102,500 $2.03 Million
Q4 2019 Jan 31, 2020	BUY	$19.49 - $32.63 $1.3 Million - $2.17 Million	66,500 New	66,500 $1.97 Million

244

56.8M

410K

394K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $90M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of Hussman Strategic Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on Hussman Strategic Advisors, Inc. with notifications on news.